Sinovac recently released its 2025 annual performance forecast. The company expects its net profit attributable to shareholders to be between RMB 135 million and RMB 175 million in 2025, representing a year-on-year increase of 328.83% to 455.89%. The company stated that this performance growth is the result of its long-term implementation of the "innovation + internationalization" dual strategy.
the innovative drug pipeline lay the foundation for revenue growth. According to reports, in 2025, Sinovac Biotech focused on the fields of oncology, autoimmune diseases, and metabolism, actively developing both first-in-class (FIC) and best-in-class (BIC) drugs. Among them, GB18 injection, a drug for treating cancer cachexia, has received clinical trial approvals from the US FDA and the Chinese NMPA, and is currently actively advancing its Phase I clinical trial in China, leading the domestic pipeline for the same target and indication. GB24, focusing on inflammatory bowel disease, is expected to address the pain points of intestinal fibrosis in patients with advanced stages, possessing the potential of a first-in-class (FIC) drug and being an important target for business development (BD) transactions in the IBD sector in recent years. GB19, targeting systemic lupus erythematosus, provides a new pathway for the treatment of autoimmune diseases, while the prospective development of the triple antibody drug GB26 aims to further seize the high ground in multispecific antibody technology. In addition, the pediatric-specific antiviral drug human interferon α1b inhalation solution is in Phase III clinical trials.
The expansion of overseas commercialization contributed to the increase in revenue. The company's overseas market layout covers more than 70 countries, and its own product EPOSINO (Epoquetin) human erythropoietin is sold in more than 30 countries and regions. According to Frost & Sullivan data, this product accounted for nearly 60% of the total export market share of similar products in 2024. The albumin-bound paclitaxel developed in cooperation with Haichang Bio is showing strong momentum, and its export volume in the first half of 2025 reached 47.7% of the export volume of similar products in China.
Sinovac Biotech stated that it will firmly focus on the main path of biopharmaceutical innovation, accelerate the global clinical development and market access of its FIC and BIC pipelines, and drive high-quality development through technological upgrades and global operations.

https://news.10jqka.com.cn/20260131/c674458130.shtml